Please login to the form below

Not currently logged in
Email:
Password:

Duchenne

This page shows the latest Duchenne news and features for those working in and with pharma, biotech and healthcare.

CHMP hands Santhera second ‘no’ in Duchenne muscular dystrophy

CHMP hands Santhera second ‘no’ in Duchenne muscular dystrophy

CHMP hands Santhera second ‘ no’ in Duchenne muscular dystrophy. Swiss biopharma says it will re-file Raxone for the licence extension. ... European regulatory advisers have refused to shift their negative position on Santhera’s Duchenne muscular

Latest news

More from news
Approximately 17 fully matching, plus 27 partially matching documents found.

Latest Intelligence

  • The challenges of making genomics a reality for patients The challenges of making genomics a reality for patients

    is site head of UK Research and vice presidet at Vertex of Duchenne UK.

  • Europe vs the US: New drug product approvals Europe vs the US: New drug product approvals

    Among the noteworthy orphan approvals are Exondys 51 (for the treatment of Duchenne muscular dystrophy, only approved in the US), Darzalex (for the treatment of multiple myeloma, approved in the US

  • Deal Watch - May 2017 Deal Watch - May 2017

    397. BMS (US). Roche (CH). Licence. Anti-myostatin adnectin pre phase 2 for Duchenne Muscular Dystrophy .

  • Deal Watch March 2017 Deal Watch March 2017

    The other asset purchase agreement was made by PTC Therapeutics, who acquired Emflaza, a steroid approved for Duchenne Muscular Dystrophy, from Marathon Pharmaceuticals for $140m upfront ($75m in cash and $65m ... 230. Marathon. PTC Therapeutics. Product

  • Deal Watch February 2017 Deal Watch February 2017

    Licence. 145. Sarepta Therapeutics/ Gilead Sciences. PRV received when EXONDYS 51 was FDA approved for Duchenne muscular dystrophy.

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest appointments

  • Catabasis hires Rick Modi as its chief business officer Catabasis hires Rick Modi as its chief business officer

    Catabasis hires Rick Modi as its chief business officer. Will help the firm develop its flagship Duchenne muscular dystrophy product. ... We look forward to leveraging his capabilities as we advance our clinical development pipeline, particularly

  • Summit appoints Pfizer/Bayer veteran as CMO Summit appoints Pfizer/Bayer veteran as CMO

    Summit appoints Pfizer/Bayer veteran as CMO. David Roblin to lead development of therapies for Duchenne muscular dystrophy and C.difficile. ... As our Duchenne muscular dystrophy and C difficile infection drug programmes go through patient clinical trials

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
McCann Health

The most globally awarded health agency network and currently Health Network agency of The Year. Comprising of two specialist agencies:...

Latest intelligence

No Voice, No Choice
Adelphi Research UK’s insights help to campaign for change in the Mental Health Act...
Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...

Infographics